khurana & khurana, advocates and IP attorneys
SUGHRUE MION, PLLC, USA
Patents have become a core part of business process, particularly for Pharmaceutical, Biotech, Chemical & Drug Industry, wherein the cost of development and protection of the portfolio is enormous. It is therefore crucial to understand important Patent issues, not only for IP team but even more importantly for R&D Scientists, so as to minimize the efforts in Patent Development and to maximize the commercial gains. It is therefore important for Corporate and concerned stakeholders to understand the nitty-gritty's of patent portfolio creation, protection, management and commercialization, without which there would always remain an open door for a serious blow either from an infringement perspective or from a patent invalidation perspective or the portfolio would remain under commercialized. This is precisely why the number of major patent litigations are growing between competitors and contemporaries, besides the growing threat from international exploiters. This Symposium features presentation of all important patent issues, as mentioned in this brochure. The speakers are a unique gathering of Patent Attorneys, Litigators and Legal Counsels, who have extensive years of experience in their professional fields. These Speakers will put across to the delegates the real insight of Patent Laws, Practices and Commercial perspectives as prevalent and practiced in the United States. The Programme will provide an opportunity to receive first-hand information including recent judgment on various issues from the experts in the fields.
Research & Development Scientists, IP Managers, Patent Agents & Attorneys in the field of Practice, Patent Litigators, Professionals in Legal Domain related to Pharma, Biotech and Chemicals.
IIPRD is a premier IP Consulting and Licensing Firm with a diversified business practice providing services in the domain of Commercialization, Valuation, Licensing, Transfer of Technology and Due-Diligence of Intellectual Property Assets along with providing complete IP and Patent Analytics and Litigation Support Services to Indian and International Corporate and Global Law Houses. IIPRD has a legacy of over fifteen years of existence, and is among the Indian IP Firms to have core focus on Commercialization, Technology Transfer, and Licensing for numerous Indian and Global Corporates.
Sughrue Mion is one of the world's leading intellectual property law firms managing traditional and non-traditional intellectual property rights, for about five decades, with a wide range of clients around the world. Sughrue's Pharmaceuticals, Biotechnology, Chemical attorneys are trained in technical disciplines that include molecular and cellular biology, biophysics, pharmaceuticals, chemistry, immunology, virology, genetics and agriculture biotechnology. Their experts are particularly well versed in drafting claims to ensure the broadest possible coverage and have a long established expertise in handling patent interference proceedings that may be critical to determining basic patent rights in new areas of biotechnological and pharmaceutical industries. Sughrue Mion handles a wide range of IP litigation matters for clients around the world.
Khurana & Khurana, Advocates and IP Attorneys (K&K) is more than a full service Intellectual Property and Commercial Law Firm. K&K was formed with a strong focus on providing end-to-end IP and Commercial Law Services along with IIPRD, which supplement each other with a core focus of acting together as a one-stop solution for all IP and Commercial Law needs. K&K has grown significantly year-on-year since establishment and is now ranked among the leading IP practices in India with recommendations and rankings from Legal 500, Managing IP, IAM, Chambers and Partners, among others. With offices in Delhi, Bangalore, and Pune, K&K caters to global clients in all main IP Litigation and Prosecution jurisdictions through its team of committed and highly qualified team of IP Attorneys.
0915-1030: Recent Federal Circuit and District Court decisions; Recent trends in the law and case law update.
1030-1130: Study of new obviousness criteria for Paragraph IV compound patent challenges post-KSR and in light of Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA (BMS v. Teva): Analyzing the criteria for lead compound analysis and understanding how BMS v. Teva will impact both prosecution and litigation under Hatch-waxman.
1145-1300:Use of IPR and other USPTO proceedings in a Paragraph IV Challenge; Review of PTAB statistics since start of AIA; PTAB's recent decisions on motion to amend and requirements of amending claims in IPR;How are Patentees adapting to PTAB challenges and what concurrent office proceedings are available to shield against such attacks?
1400-1500:Incorporating major changes under the AIA including inter partes review (IPR) and post-grant review (PGR) into pharmaceutical prosecution and litigation strategies;Top patent disputes to consider when streamlining pharmaceutical prosecution and litigation strategies.
1500-1600:Is a patent application correctly filed in the name of the applicant or should it be filed in the name of the inventors because it is under the old 120/119(e)? A discussion of best practices for electing the assignee(s) or inventor(s) of an application filed prior to, but prosecuted after the implementation of AIA; Best practices for correcting errors regarding inventorship and outline lessons from recent court decisions. 1600-1615:Tea Break
1615-1715:US Supreme Court and Patent law Part I: The Supreme Court has issued decisions in six patent cases this year. How do the Supreme Court decisions affect the patent landscape for pharma/biotech ? Practice tips in view of the Supreme Court decisions.
0915-1015:US Supreme Court and Patent Law Part II: The Supreme Court has issued decisions in six patent cases this year. How do the Supreme Court decisions affect the patent landscape for pharma/biotech? Practice tips in view of the Supreme Court decisions.
1015-1115:Exploring IP and Litigation Strategies for Biosimilar Development in the United States; Jumping the gun in Sandoz v. Amgen and Celltrion v. Janssen,Discussion of the Regulatory and Exclusivity Considerations for Biosimilar Pathway.
1130-1300:Patent prosecution tips in light of the recently issued FDA guidance on the regulatory classification of pharmaceutical co-crystals, and a discussion of other recent FDA guidance for industry.
1400-1500:Advanced Strategies for Pleading and Effectively Using Motions Practice in Paragraph IV Disputes; New Exclusivity Challenges for Brand Names and Generic and Related Implications for Paragraph IV Challenge.
1500-1600:Best Practices to Secure Patent Allowance using Evidence: Evidentiary declarations under the to File system including declarations relating to the 1-year grace period under the new section 102(b); How Rule 132 declarations and other evidence are explained to overcome obviousness rejections; How to avoid common pitfalls that can sink a patent during litigation;
1615-1730:Recent developments for Patent Term Adjustments (PTA) in view of Exelixis and Novartis, and their potential impact, methods for calculating PTA, what can be done to preserve rights, and best practices for maximizing PTA; discussion of proposed guidance for calculating patent term adjustments.
Mr. Chid Iyer Chid received a B. Tech in Chemical Engineering from IIT, Bombay in 1984, MS in Chemical Engineering from University of Akron and MS in Computer Science from the University of Tennessee Space Institute. He received his JD from Georgetown University in 1997. Chid is a partner of International Law Firm of Sughrue Mion and is involved in all aspects of patent practice including litigation, prosecution and client counselling in a variety of technologies with focus on chemical and pharmaceutical. Chid has prepared and prosecuted over 100 applications for a leading research laboratory.
Mr. Michael R. Dzwonczyk Michael is a partner at Sughrue Mion and has about 20 years of experience in successfully representing multinational companies in patent litigation, including trials and appeals of patent cases. His experience has encompassed technical areas that include pharmaceuticals, recombinantly produced hormones, protein synthesis and expression products, fibers, and medical devices. Michael also counsels clients on intellectual property issues, including validity and infringement of intellectual property rights, licensing and contract matters and Hatch-Waxman issues.
Ms. Azy S. Kokabi Azy S. Kokabi's practice focuses on worldwide procurement, defense and enforcement of patents in the biotechnology and pharmaceutical industries, with focus on prosecution, interference, and litigation motions practice. Kokabi did her post graduation in Biology and JD from George Mason University School of Law. Kokabi has served as counsel in interference proceedings and related matters, before the Board of Patent Appeals and Interferences and the Court of Appeals for the Federal Circuit. Prior to joining Sughrue Mion, Ms. Kokabi also served at the U.S. Patent and Trademark Office as an Examiner.
Mr. Travis Ribar Ribar practices in all areas of intellectual property law with a focus on rendering opinions on patentability, infringement, and validity, including due diligence and product clearance analysis, as well as on the litigation of intellectual property matters, including re-examination practice. A former Patent Examiner at the USPTO, he also counsels and assists clients in the procurement of both U.S. and foreign patents, which includes the preparation and prosecution of patent applications. Ribar specializes in the areas of photoresist formulations and applications, rubber compositions, plastics and adhesives, membranes, medical devices etc.
Ms. Deb Sengupta Deb is an associate in the firm's Chemical/Biotech Practice Group. Her practice includes patent prosecution and litigation support, and client counseling, primarily within the areas of organic and materials chemistry, pharmaceuticals and nano-devices. Dr. Sengupta joined Sughure Mion upon receiving her Ph.D in Chemistry from Cornell University. Her thesis was entitled "Surface Functionalization of MHz-Range Silicon Resonators: Controlling Mechanical Energy Dissipation and Adding Chemical Functionality." During her graduate carrer, Dr. Sengupta fabricated silicon nanomechanical devices utilizing the clean-room facilities at the Cornell NanoSacle Science and technology Facility.
Indian Delegates : INR 9,000/- Per Delegate (If 3 or more delegates are nominated by any company, delegate fees will be Rs. 7000/- Per delegate)
Foreign Delegates : USD 250 Per Delegate
Please Forward the Delegate Fees with the following details:
Name, Organization, Designation, Address and Contact Details along with the cheque drawn in favour of " M/S IIPRD " to Mr. Tarun Khurana
IIPRD, E-13, UPSIDC Site-IV, Kasna Road, Greater Noida-201308, UP, India
Ms. Meenakshi Khurana
Mr. Tarun Khurana,
Email: firstname.lastname@example.org, email@example.com
Ph : +91-120-2342010/4296878, Fax: +91-120-2342011